Suppr超能文献

FRAX 在前列腺癌男性患者中的表现:基于注册的队列研究。

Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study.

机构信息

University of Alberta, Edmonton, Canada.

McGill University, Montreal, Canada.

出版信息

J Bone Miner Res. 2023 May;38(5):659-664. doi: 10.1002/jbmr.4793. Epub 2023 Mar 6.

Abstract

The Fracture Risk Assessment Tool (FRAX®) was created to predict major osteoporotic fractures (MOF) and hip fractures in the general population. Whether FRAX accurately predicts fractures in men with prostate cancer is unknown. Our objective was to assess the performance of FRAX for predicting incident fractures in men with prostate cancer. Men from the Manitoba Bone Mineral Density (BMD) Registry (1996-2018) with prostate cancer diagnoses in the 3 years prior to dual-energy X-ray absorptiometry (DXA) were identified. FRAX scores with and without BMD were calculated. From population-based healthcare data we identified incident MOF, hip fracture, any osteoporotic fracture and death from the date of BMD testing to March 31, 2018. Cox regression was performed to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs) per standard deviation increase in FRAX score. Observed 10-year probability (estimated with competing risk of mortality) was compared with 10-year FRAX-predicted fracture probability to assess calibration. The study population included 684 men with prostate cancer (mean age 74.6 years) and 8608 men without prostate cancer (mean age 65.5 years). FRAX stratified risk for MOF (HR 1.91, 95% CI 1.48-2.45 with BMD; HR 1.96, 95% CI 1.43-2.69 without BMD) and hip fracture (HR 3.37, 95% CI 1.90-6.01 with BMD; HR 4.58, 95% CI 2.17-9.67 without BMD) in men with prostate cancer. There was no effect modification observed with prostate cancer status or current androgen deprivation therapy. Observed 10-year fracture probability in men with prostate cancer showed good agreement with FRAX with and without BMD included in the calculation (observed/predicted calibration ratios MOF 0.97, hip 1.00 with BMD; MOF 0.92, hip 0.93 with BMD). In conclusion, FRAX reliably predicts incident fractures in men with prostate cancer. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

摘要

骨折风险评估工具 (FRAX®) 的创立旨在预测普通人群中的主要骨质疏松性骨折 (MOF) 和髋部骨折。FRAX 是否能准确预测前列腺癌男性的骨折尚不清楚。我们的目的是评估 FRAX 预测前列腺癌男性骨折的能力。从 1996 年至 2018 年,从马尼托巴省骨密度 (BMD) 登记处(Manitoba Bone Mineral Density (BMD) Registry)中确定了在双能 X 射线吸收法 (DXA) 检测前 3 年内被诊断患有前列腺癌的男性。计算了有和没有 BMD 的 FRAX 评分。根据基于人群的医疗保健数据,我们确定了从 BMD 检测日期到 2018 年 3 月 31 日的 MOF、髋部骨折、任何骨质疏松性骨折和死亡的发病情况。使用 Cox 回归估计 FRAX 评分每增加一个标准差的风险比 (HR) 及其 95%置信区间 (95%CI)。通过竞争死亡率的风险来比较观察到的 10 年概率(用竞争风险的死亡率来估计)和 10 年 FRAX 预测的骨折概率,以评估校准。研究人群包括 684 名患有前列腺癌的男性(平均年龄 74.6 岁)和 8608 名没有前列腺癌的男性(平均年龄 65.5 岁)。FRAX 对 MOF(有 BMD 的 HR 为 1.91,95%CI 为 1.48-2.45;无 BMD 的 HR 为 1.96,95%CI 为 1.43-2.69)和髋部骨折(有 BMD 的 HR 为 3.37,95%CI 为 1.90-6.01;无 BMD 的 HR 为 4.58,95%CI 为 2.17-9.67)的风险进行了分层。未观察到前列腺癌状态或当前雄激素剥夺治疗对风险分层的影响。在考虑 BMD 纳入计算的情况下,前列腺癌男性的观察到的 10 年骨折概率与 FRAX 具有良好的一致性(MOF 的观察/预测校准比为 0.97,髋部为 1.00;MOF 的观察/预测校准比为 0.92,髋部为 0.93)。总之,FRAX 可靠地预测了前列腺癌男性的骨折发病情况。© 2023 作者。《骨与矿物质研究杂志》由 Wiley 期刊出版公司代表美国骨与矿物质研究协会 (ASBMR) 出版。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验